Designed to be used simply and anonymously, the system can verify vaccination status, whenever and wherever required.
The enrollment component of the Barcodes, Inc./VAXSYS System is mobile, accurate and paper free, providing the ability to print and issue durable, legible vaccine credentials on secure plastic VAXSYS Cards that contain an encrypted, fraud-resistant 2D barcode.
Providing all necessary hardware and software, the System can be operated in stand-alone mode, or integrated into a user database at the option of the user.
The Verification component of the Barcodes, Inc./VAXSYS System is a mobile App which can be downloaded on to any Android handheld device with 2D barcode reading capability.
The App decrypts the barcode on the VAXSYS Card to generate an anonymous, immediate, level-1 proof of COVID-19 vaccination, without requiring any additional personal, biographic or biometric information from the holder.
Barcodes, Inc., headquartered in Chicago, IL and with corporate locations across the US, Canada, and Europe, is a leading information technology solution provider with more than a 26-year history of providing products, software, and services to automate businesses.
The company's data capture products, which include barcoding, RFID, mobile, people identification, and wireless networking devices, and integration and managed services enable customers to improve productivity and profitability in their businesses.
Based in Calabasas, California, VAXSYS Technologies was founded by biometric and identification industry professionals, dedicated to helping society use simple and secure vaccination enrollment and screening technologies to help return us back to normal.
By combining best-in-class ID scanning and verification capabilities, with our collective experience servicing large and complex government entities, VAXSYS provides a full suite of Apps that enable the end-to-end usage of vaccination data by vaccinators, and by the general public who need to screen people entering buildings or businesses.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine